Flowcharts
Every urology cancer as a single connected pathway. Follow the constellation of phases from first suspicion to the final line of treatment.
Bladder Cancer
The complete EAU-aligned bladder cancer pathway — from haematuria work-up through NMIBC risk groups, MIBC management, BCG failure, adjuvant therapy and metastatic lines of treatment. Switch between the visual Pathway map and a step-by-step Guided tool.
Penile Cancer
The EAU/ESMO penile cancer pathway — from clinical suspicion and biopsy through TNM staging, stage-directed primary-tumour treatment, risk-based inguinal lymph node management, and metastatic disease. Switch between the visual Pathway map and the phase-by-phase Explorer.
Prostate Cancer
The complete EAU prostate cancer pathway — from PSA testing and mpMRI/biopsy through risk stratification, curative treatment (active surveillance, surgery, radiotherapy), adjuvant therapy and recurrence, metastatic hormone-sensitive disease and castration-resistant treatment lines. Switch between the visual Pathway map and the phase-by-phase Explorer.
Renal Cell Carcinoma
The EAU renal cell carcinoma pathway — from clinical suspicion or incidental finding through diagnosis, cT staging and chest imaging, localized treatment (partial/radical nephrectomy, ablation, active surveillance, adjuvant pembrolizumab), follow-up and recurrence, to metastatic care: oligo/metastasis-directed therapy, IMDC risk stratification, and histology-directed systemic therapy for clear-cell and non-clear-cell disease. Switch between the visual Pathway map and the phase-by-phase Explorer.
Testicular Cancer
The EAU testicular (germ-cell) cancer pathway — from clinical suspicion through ultrasound, tumor markers and inguinal orchiectomy to histology (seminoma vs non-seminoma), CT/IGCCCG staging, and stage- and histology-directed treatment: Stage I/II seminoma (surveillance, carboplatin, radiotherapy, RPLND) and non-seminoma (surveillance, adjuvant PEB, primary RPLND, chemotherapy), advanced/metastatic disease by IGCCCG prognosis, post-chemotherapy restaging and residual-mass management, and relapse. Switch between the visual Pathway map and the phase-by-phase Explorer.
Upper Tract Urothelial Carcinoma
The EAU upper tract urothelial carcinoma (UTUC) pathway — from clinical suspicion through CT-urography, ureteroscopy and urine cytology to diagnosis (with germline/Lynch testing), CT staging and risk stratification, and risk-directed treatment: kidney-sparing surgery for low-risk disease, radical nephroureterectomy with bladder-cuff (± lymphadenectomy, adjuvant chemo/IO) for high-risk and cN+, metastatic systemic therapy (EVP / platinum chemo ± IO / avelumab maintenance / later lines), and risk-based follow-up. Switch between the visual Pathway map and the phase-by-phase Explorer.